Objective To study the effect of immunotherapy on expression of CD14+mHLA-DR and the serum levels of immunoglobulin (IgG, IgA and IgM) in patients with severe pneumonia, so as to discuss the feasibility of immunotherapy for severe pneumonia. Methods From January 2012 to April 2014, 120 cases of patients with severe pneumonia treated in the intensive care unit (ICU) and pneumonia department were collected. Patients were randomly divided into control group (60 cases) and treatment group (60 cases). The control group was administrated with conventional therapy , and the treatment group was given thymosin α1 for immune treatment for 7 days. The mHLA-DR expression and the level of IgG , IgA and IgM of the two groups before and after the treatment were compared. Results After thymosin α1 treatment, mHLA-DR expression rate was elevated , and the serum levels of IgG , IgA and IgM were elevated in the treatment group , and the difference was statistically significant (P < 0.05). While there was no statistically significant difference betweenthe above indicators before and after treatment (P > 0.05). Conclusion After immune treatment with the use of thymosin α1 , immunologic suppression can be prevented , and cellar immune function of severe pneumonia patients can be improved.

Objective To observe the efficacy of Zishen Ningxin capsule combined with telmisartan in the treatment of perimenopausal hypertension,and its influence on the patients'blood pressure,biochemical indexes and TCM symptom scores.Methods 300 patients with perimenopausal hypertension were randomly divided into control group and observation group with 150 patients in each group.The control group was given telmisartan treatment,and the observation group was given Zishen Ningxin capsule on the basis of the control group.The treatment course of both groups was 8 weeks.The dynamic blood pressure and coefficient of variation of blood pressure at 24 h before and after treatment were observed and compared between two groups(24 h systolic blood pressure and coefficient of variation,24 h diastolic blood pressure and its coefficient of variation),sex hormone levels(serum estradiol,follicle stimulating hormone,testosterone,progesterone),blood lipid levels(triacylglycerol,total cholesterol,low density lipoprotein cholesterol,high density lipoprotein cholesterol),renin and hypersensitive C-reactive protein levels,as well as the changes of TCM symptom score were evaluated for the efficacy of the two groups.Results After treatment,the 24 h systolic blood pressure and its coefficient of variation,24 h diastolic blood pressure and its coefficient of variation,the levels of sex hormones,blood lipids,renin and hypersensitive C-reactive protein,as well as TCM symptom scores in two groups were significantly improved(P＜0.05),and all indexes in the observation group were better than those in the control group(P＜0.05).The total effective rate of observation group was significantly higher than that of control group(P＜0.05).There was no significant difference of the incidence of adverse reactions in the two groups(P＞0.05).Conclusion Zishen Ningxin capsule combined with telmisartan has significant clinical efficacy in the treatment of perimenopausal hypertension,which can effectively reduce blood pressure,relieve symptoms,improve the levels of sex hormones,blood lipids,renin and hypersensitive C-reactive protein.

Blood-brain barrier (BBB) damage after ischemia significantly influences stroke outcome. Compound LFHP-1c was previously discovered with neuroprotective role in stroke model, but its mechanism of action on protection of BBB disruption after stroke remains unknown. Here, we show that LFHP-1c, as a direct PGAM5 inhibitor, prevented BBB disruption after transient middle cerebral artery occlusion (tMCAO) in rats. Mechanistically, LFHP-1c binding with endothelial PGAM5 not only inhibited the PGAM5 phosphatase activity, but also reduced the interaction of PGAM5 with NRF2, which facilitated nuclear translocation of NRF2 to prevent BBB disruption from ischemia. Furthermore, LFHP-1c administration by targeting PGAM5 shows a trend toward reduced infarct volume, brain edema and neurological deficits in nonhuman primate